About Viking Therapeutics
Viking Therapeutics is a company based in United States founded in 2012.. Viking Therapeutics has raised $2.5 million across 1 funding round from investors including Ligand Pharmaceuticals. The company has 36 employees as of December 31, 2024. Viking Therapeutics offers products and services including VK2735, VK2809, VK0214, and VK5211. Viking Therapeutics operates in a competitive market with competitors including Neurocrine, Crinetics, Carmot, Zucara Therapeutics and MBX Biosciences, among others.
- Headquarter California, United States
- Employees 36 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Viking Therapeutics, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-359.64 M-227.05as on Dec 31, 2025
-
EBITDA
$-392.91 M-160.94as on Dec 31, 2025
-
Total Equity Funding
$2.5 M (USD)
in 1 rounds
-
Latest Funding Round
$2.5 M (USD), Seed
May 22, 2014
- Investors
-
Employee Count
36
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Viking Therapeutics
Viking Therapeutics is a publicly listed company on the NASDAQ with ticker symbol VKTX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Viking Therapeutics
Viking Therapeutics offers a comprehensive portfolio of products and services, including VK2735, VK2809, VK0214, and VK5211. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Therapeutic for obesity and metabolic disorders via oral administration.
Treatment for NASH and related metabolic conditions.
Therapy for rare disease X-ALD.
addresses hip fracture and muscle wasting.
Unlock access to complete
Funding Insights of Viking Therapeutics
Viking Therapeutics has successfully raised a total of $2.5M through 1 strategic funding round. The most recent funding activity was a Seed round of $2.5 million completed in May 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Seed — $2.5M
-
First Round
First Round
(22 May 2014)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2014 | Amount | Seed - Viking Therapeutics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Viking Therapeutics
Viking Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Ligand Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical drugs are manufactured and developed in the United States.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Viking Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Viking Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Viking Therapeutics Comparisons
Competitors of Viking Therapeutics
Viking Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Neurocrine, Crinetics, Carmot, Zucara Therapeutics and MBX Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
|
| domain | founded_year | HQ Location |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes
|
|
| domain | founded_year | HQ Location |
Drugs for rare endocrine diseases are developed and advanced.
|
|
| domain | founded_year | HQ Location |
Protein therapies for diabetes and gastrointestinal diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Viking Therapeutics
Frequently Asked Questions about Viking Therapeutics
When was Viking Therapeutics founded?
Viking Therapeutics was founded in 2012 and raised its 1st funding round 2 years after it was founded.
Where is Viking Therapeutics located?
Viking Therapeutics is headquartered in United States. It is registered at California, United States.
Who is the current CEO of Viking Therapeutics?
Brian Lian is the current CEO of Viking Therapeutics.
Is Viking Therapeutics a funded company?
Viking Therapeutics is a funded company, having raised a total of $2.5M across 1 funding round to date. The company's 1st funding round was a Seed of $2.5M, raised on May 22, 2014.
How many employees does Viking Therapeutics have?
As of Dec 31, 2024, the latest employee count at Viking Therapeutics is 36.
What does Viking Therapeutics do?
Viking Therapeutics was founded in 2012 in California, United States, and operates in the biotechnology sector. A portfolio of five therapeutic programs based on small molecules is maintained, targeting endocrine and metabolic disorders. The lead candidate, VK0612, is an oral drug for type 2 diabetes, while VK5211 serves as a non-steroidal selective androgen receptor modulator for cancer cachexia. Three preclinical programs address metabolic diseases and anemia.
Who are the top competitors of Viking Therapeutics?
Viking Therapeutics's top competitors include Crinetics, Neurocrine and Zucara Therapeutics.
What products or services does Viking Therapeutics offer?
Viking Therapeutics offers VK2735, VK2809, VK0214, and VK5211.
Is Viking Therapeutics publicly traded?
Yes, Viking Therapeutics is publicly traded on NASDAQ under the ticker symbol VKTX.
Who are Viking Therapeutics's investors?
Viking Therapeutics has 1 investor. Key investors include Ligand Pharmaceuticals.
What is Viking Therapeutics's ticker symbol?
The ticker symbol of Viking Therapeutics is VKTX on NASDAQ.